Immune Checkpoint Inhibitor Therapy Tied to Cardiac Event Risk

Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA - 4i
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Dermatology, Oncology, Pharmacy, Pulmonology, Journal, Source Type: news